Companies: 10,795·Total market cap: $144.5T
Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc.

LYRANASDAQHealthcare
$0.44
$-0.06(-11.98%)
Market Cap$781126
P/E Ratio
52W High$37.5
52W Low$0.4401
Overview

Lyra Therapeutics, Inc. (LYRA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · LYRA · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-18.62lyra eps ttm · lyra earnings per shareEarnings history
PE Ratio (TTM)lyra pe ratio ttm · lyra price to earningsPE Ratio deep dive
Revenue (TTM)398000.00lyra revenue ttm · lyra annual revenueFull revenue history
Dividend YieldNo Dividenddoes lyra pay dividends · lyra dividend yieldDividend history
Shares Outstanding15.5Mlyra shares outstanding · lyra floatShares outstanding history
Next EarningsTBAlyra earnings date · lyra next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$398000.00▼ 74.05% YoY
202320242025
lyra therapeutics, inc. revenue · lyra revenue 2025
FY 2025Net Income-$28.9M▲ +69.05% YoY
202320242025
lyra therapeutics, inc. net income · lyra profit 2025
FY 2025EPS$-18.62▼ 1202.10% YoY
202320242025
lyra eps · lyra therapeutics, inc. earnings per share 2025
TTM:Revenue: $398000.00Net Income: -$28.9MEPS: $-18.62View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Hold5 analystsis lyra a buy · lyra analyst rating
Strong Buy
0
Buy
2
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$0.50Low
$0.44Current
$0.50Avg Target13.61% upside
$0.50High
lyra price target · lyra 12 month forecast

Total: 5 · Buy rate: 40.0%

The LYRA analyst consensus is Hold, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $0.50, representing +13.61% upside from the current price of $0.44.

Stock Performance

Full History
1D+0.00%
1W-16.96%
1M-11.98%
3M-77.88%
YTD-85.71%
1Y-89.81%
5Y-99.92%

About Lyra Therapeutics, Inc.

CEOCarmichael S. Roberts Jr.
IPO DateMay 1, 2020
Employees30
CountryUS

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chron…

what is lyra therapeutics, inc. · lyra stock overview · lyra therapeutics, inc. company profile · who is lyra therapeutics, inc. ceo · lyra NASDAQ · lyra therapeutics, inc. headquarters · lyra therapeutics, inc. business segments

About Stock Overview & Key Data

Lyra Therapeutics, Inc. (LYRA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 1, 2020. As of the latest trading session, LYRA stock price is $0.44, with a market capitalization of $781,126. The stock has returned -89.81% over the past 12 months and -85.71% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Lyra Therapeutics, Inc. stock is Hold, with an average 12-month price target of $0.50. In fiscal year 2025, Lyra Therapeutics, Inc. reported revenue of $398000.00 and net income of -$28.9M. For detailed data — including Lyra Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Lyra Therapeutics, Inc. (LYRA) stock price is $0.44. The stock is traded on NASDAQ under the ticker symbol LYRA. The 52-week range is $0.44 – $37.50.

LYRA stock priceLYRA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice